<DOC>
	<DOCNO>NCT00347061</DOCNO>
	<brief_summary>Primary : To assess safety SL77.0499-10 10mg administer daily one year patient low urinary tract symptom relate BPH . Secondary : - To provide information efficacy SL77.0499-10 10mg administer daily one year patient low urinary tract symptom relate BPH . - To document plasma concentration SL77.0499-10 repeat administration SL77.0499-10 10mg administer daily patient low urinary tract symptom relate BPH .</brief_summary>
	<brief_title>Long Term Safety SL77.0499-10 ( Alfuzosin ) Patients With BPH</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>Having symptomatic BPH diagnose clinically digital rectal examination ultrasonography Suffering least 6 month low urinary tract symptom relate BPH An IPSS total score ≥ 13 Out patient Patients previously treat SL77.049910 . Neurogenic bladder dysfunction , confirm suspect , irrespective aetiology . Isolated bladder neck disease . Diagnosed carcinoma prostate . Previous prostatic surgery invasive procedure ( thermotherapy… ) treatment BPH . Patients indwell catheter . A residual urine &gt; 200mL . Patients Moderate sever hepatic insufficiency . Known hypersensitivity alpha1blockers . Patients receive antiandrogens , 5alphareductase inhibitor , LHRH analogue within previous 3 month Screening Patients judged inappropriate admission study Investigator SubInvestigator .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Benign Prostatic Hyperplasiam</keyword>
	<keyword>Adrenergic alpha-antagonist</keyword>
</DOC>